Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

Essential Fatty Acid Deficiency (EFAD) Clinical Trial

Official title: A Randomized, Double-Blind, Controlled, Clinical Trial to Evaluate the Risk of Developing Essential Fatty Acid Deficiency in Pediatric Patients, Including Neonates, Receiving Either Clinolipid (Lipid Injectable Emulsion, USP) 20% or Standard-of-Care Soybean Oil-Based Lipid Emulsion

Status Terminated

Clinical Trial Summary

This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care for up to 90 days to develop Essential Fatty Acid Deficiency (EFAD). Additionally, this study design will evaluate the safety and efficacy of using Clinolipid in a pediatric population.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Essential Fatty Acid Deficiency (EFAD)

• NCT number: NCT02476994
• Study type: Interventional
• Source: Baxter Healthcare Corporation
• Status: Terminated
• Phase: Phase 4
• Start date: May 2015
• Completion date: October 2016